Short acting GLP-1 receptor agonist (injectable)
Lixisenatide injection
LIXI_SC
Doses in this pooled treatment
- Lixisenatide 20 ug subcutaneous once daily
- Lixisenatide 5 µg injection once daily
- Lixisenatide 10 µg injection once daily
- Lixisenatide 30 µg injection once daily
- Lixisenatide 5 µg injection twice daily
- Lixisenatide 10 µg injection twice daily
- Lixisenatide 20 µg injection twice daily
- Lixisenatide 30 µg injection twice daily
- Lixisenatide 10 µg injection
- Lixisenatide 2.5 µg injection
- Lixisenatide 5 µg injection
- Lixisenatide 20 µg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.37 (-0.75 to 0.02) | 0.15 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.41 (-0.77 to -0.06) | 0.19 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin glargine | MD 0.50 (-0.56 to 1.47) | 0.08 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.88 (-1.51 to -0.20) | 0.54 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.55 (-0.99 to -0.12) | 0.99 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.58 (-0.92 to -0.14) | 0.60 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.30 (-1.37 to 0.73) | 0.35 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.39 (-2.66 to -0.17) | 0.49 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.16 (-2.72 to 0.47) | 0.68 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin glargine | MD -2.84 (-7.17 to 2.30) | 0.82 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.97 (-2.23 to 0.35) | 0.96 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.53 (-1.65 to 0.58) | 0.49 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.86 (-5.99 to 4.00) | 0.45 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 1.91 (0.67 to 3.92) | 0.13 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 2.02 (1.17 to 3.26) | 0.21 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Insulin glargine | OR 0.28 (0.10 to 0.91) | 0.01 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 2.73 (1.52 to 4.90) | 1.00 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 2.00 (0.47 to 6.55) | 0.49 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.36 (0.08 to 1.28) | 0.43 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.64 (0.30 to 1.36) | 0.85 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.61 (1.14 to 2.34) | 0.47 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.55 (0.12 to 2.23) | 0.67 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 3.30 (-3.36 to 9.85) | 0.13 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.60 (0.48 to 5.18) | 0.23 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.63 (0.59 to 4.47) | 0.39 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.78 (1.08 to 2.95) | 0.98 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.56 (0.40 to 5.75) | 0.49 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.03 (0.85 to 1.27) | 0.44 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.23 (1.41 to 3.41) | 0.32 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.22 (3.39 to 5.36) | 0.22 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.66 (3.43 to 6.57) | 0.23 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.19 (0.97 to 1.47) | 0.57 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.57 (1.03 to 2.49) | 0.45 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 6.67 (1.54 to 33.12) | 0.17 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.26 (0.02 to 2.48) | 0.66 |
| Children and adolescents with type 2 diabetes | Serious adverse events | longest follow-up | Placebo | HR 1.94 (0.07 to 96.27) | 0.35 |
| Children and adolescents with type 2 diabetes | Nausea | longest follow-up | Placebo | HR 0.69 (0.06 to 10.73) | 0.70 |
| Children and adolescents with type 2 diabetes | Vomiting | longest follow-up | Placebo | HR 3.33 (0.17 to 127) | 0.38 |
| Chronic kidney disease with diabetes | Serious adverse events | longest follow-up | Placebo | HR 1.60 (0.31 to 9.61) | 0.38 |
| Chronic kidney disease with diabetes | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.37 (0.21 to 9.91) | 0.63 |
| Chronic kidney disease with diabetes | Nausea | longest follow-up | Placebo | HR 1.17 (0.24 to 5.56) | 0.70 |
| Chronic kidney disease with diabetes | Vomiting | longest follow-up | Placebo | HR 1.39 (0.19 to 11.24) | 0.77 |
| Chronic kidney disease with diabetes | Diarrhea | longest follow-up | Placebo | HR 1.29 (0.23 to 8.03) | 0.71 |
| Chronic kidney disease with diabetes | Constipation | longest follow-up | Placebo | HR 1.66 (0.16 to 21.28) | 0.57 |
Trials
- S002858101 randomized · 24 weeks
- S00305848 randomized · 12 weeks
- Lixilan-O-APA Randomized, 24 Week, Active-controlled, Open-label, 3-arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to Insulin Glargine and Lixisenatide in Type 2 Diabetes Mellitus Patients Insufficiently Controlled With Oral Antidiabetic Drug(s)2019 · 878 randomized · 24 weeks
- NCT02803918Randomized, Double-blind, Placebo-controlled, Dose Escalation, Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin and/or Basal Insulin2017 · 23 randomized · 6 weeks
- LIXILAN JP-O1A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Combination to Lixisenatide on Top of OADs in Japanese Patients With Type 2 DM With an Extension Period2016 · 321 randomized · 52 weeks
- NCT02200991A Randomized, Multicenter, Open-Label, Parallel-Group, 28 Days Phase IV Study Comparing The Postprandial Plasma Glucose Profile of Lixisenatide With That of Sitagliptin Add-On to Insulin Glargine in Type 2 Diabetes Mellitus2014 · 136 randomized · 4 weeks
- LixiLan-OA Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)2014 · 1,170 randomized · 30 weeks
- GetGoal-OA Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen2013 · 350 randomized · 24 weeks
- NCT01632163A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Metformin2012 · 448 randomized · 24 weeks
- GetGoal-M-AsiaEfficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (With or Without Sulfonylurea): a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With 24-week Treatment Period2010 · 391 randomized · 24 weeks
- NCT01175473An Open-label, Randomized Two-arm Parallel Group Study to Compare the Effects of 4-week QD Treatment With Lixisenatide or Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin2010 · 148 randomized · 4 weeks
- GETGOAL-L-ASIAA Randomized, Double-Blind, Placebo-Controlled, 2-arm Parallel-group, Multicenter Study With a 24-Week Treatment Period Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Sulfonylurea2009 · 311 randomized · 24 weeks
- GetGoal-Duo1A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin2009 · 446 randomized · 24 weeks
- NCT00976937A Randomized, Double-blind, Double-dummy, 2-arm Parallel-group, Multicenter 24-week Study Comparing the Efficacy and Safety of AVE0010 to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 and Not Adequately Controlled With Metformin2009 · 319 randomized · 24 weeks
- GETGOAL-PA Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Pioglitazone in Patients With Type 2 Diabetes Not Adequately Controlled With Pioglitazone2008 · 484 randomized · 24 weeks
- GETGOAL-SA Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of a Sulfonylurea in Patients With Type 2 Diabetes Not Adequately Controlled With Sulfonylurea2008 · 859 randomized · 24 weeks
- GETGOAL-XA Randomized, Open-label, Active-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 Versus Exenatide on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin2008 · 639 randomized · 24 weeks
- GETGOAL-LA Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin2008 · 496 randomized · 24 weeks
- S0030472006 · 120 randomized · 6 weeks
- NCT00299871A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus2006 · 542 randomized · 13 weeks